Testicular Functions and Clinical Characterization of Patients with Gender Dysphoria (GD) Undergoing Sex Reassignment Surgery (SRS)

J Sex Med. 2015 Nov;12(11):2190-200. doi: 10.1111/jsm.13022. Epub 2015 Nov 12.

Abstract

Introduction: Cross-sex hormone treatment of gender dysphoria (GD) patients changing from male to female a prerequisite for sex reassignment. For initial physical adaptation, a combined treatment of anti-androgens and estrogens is used. Provided that patients fulfill specific criteria, sex reassignment surgery (SRS) presents the final step toward physical adaptation. However, systematic studies analyzing effects of hormone treatment regimens are lacking.

Aim: The aim of this study was to compare the effects of three different hormonal treatment strategies regarding endocrinological parameters and testicular histology.

Methods: Testicular tissues were obtained in a multicenter study from 108 patients on the day of SRS from three clinics following different treatment strategies. Patients either discontinued treatment 6 weeks (clinic A) or 2 weeks (clinic B) prior to SRS or not at all (clinic C). Testicular tissues, ethylenediaminetetraacetic acid blood and questionnaires were obtained on the day of SRS.

Main outcome measures: Blood hormone and intratesticular testosterone (ITT) levels were measured. Testicular weight and histology were evaluated and the percentage of luteinizing hormone/choriogonadotropin receptor (LHCGR) positive cells was determined.

Results: According to the questionnaires, patients showed desired phenotypical changes including breast growth (75%) and smooth skin (32%). While patients from clinics A and B presented with rather virilized hormonal levels, patients from clinic C showed generally feminized blood serum levels. Histological evaluation revealed highly heterogeneous results with about 24% of patients presenting with qualitatively normal spermatogenesis. In accordance with serum endocrine profile, ITT levels were lowest in clinic C and correlated with testosterone and free testosterone, but not with the spermatogenic state. The percentage of LHCGR-positive cells and ITT levels did not correlate.

Conclusion: Only patients that did not discontinue hormonal treatment showed feminized blood levels on the day of SRS. The ones who stopped re-virilized quickly. Interestingly, testicular histology was highly heterogeneous irrespective of the treatment strategy, a phenomenon that requires further investigation.

Keywords: Cross-Sex Hormone Therapy; Gender Dyshoria; Spermatogenesis; Steroidogenesis; Testicular Tissue; Transsexual Patients.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Androgen Antagonists / therapeutic use
  • Estrogens / therapeutic use
  • Female
  • Gender Dysphoria / psychology*
  • Gender Dysphoria / surgery
  • Germany / epidemiology
  • Gonadal Steroid Hormones / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Sex Reassignment Surgery / methods*
  • Spermatogenesis / drug effects*
  • Surveys and Questionnaires
  • Testis / physiopathology*
  • Testis / surgery
  • Testosterone / blood
  • Transgender Persons / psychology*

Substances

  • Androgen Antagonists
  • Estrogens
  • Gonadal Steroid Hormones
  • Testosterone